Altered Cerebral Blood Flow and Potential Neuroprotective Effect of Human Relaxin-2 (Serelaxin) During Hypoxia or Severe Hypovolemia in a Sheep Model.

Autor: Schiffner R; Zentrale Notaufnahme, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.; Orthopedic Department, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany., Bischoff SJ; Institute for Laboratory Animal Science and Welfare, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany., Lehmann T; Institute of Medical Statistics, Computer Sciences and Documentation Science, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany., Irintchev A; Department of Otorhinolaryngology, Jena University Hospital, Friedrich Schiller University, 07747 Jena, Germany., Nistor M; Orthopedic Department, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany., Lemke C; Institute for Anatomy I, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany., Schmidt M; Institute for Biochemistry II, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2020 Feb 27; Vol. 21 (5). Date of Electronic Publication: 2020 Feb 27.
DOI: 10.3390/ijms21051632
Abstrakt: Specific neuroprotective strategies to minimize cerebral damage caused by severe hypoxia or hypovolemia are lacking. Based on previous studies showing that relaxin-2/serelaxin increases cortical cerebral blood flow, we postulated that serelaxin might provide a neuroprotective effect. Therefore, we tested serelaxin in two emergency models: hypoxia was induced via inhalation of 5% oxygen and 95% nitrogen for 12 min; thereafter, the animals were reoxygenated. Hypovolemia was induced and maintained for 20 min by removal of 50% of the total blood volume; thereafter, the animals were retransfused. In each damage model, the serelaxin group received an intravenous injection of 30 µg/kg of serelaxin in saline, while control animals received saline only. Blood gases, shock index values, heart frequency, blood pressure, and renal blood flow showed almost no significant differences between control and treatment groups in both settings. However, serelaxin significantly blunted the increase of lactate during hypovolemia. Serelaxin treatment resulted in significantly elevated cortical cerebral blood flow (CBF) in both damage models, compared with the respective control groups. Measurements of the neuroproteins S100B and neuron-specific enolase in cerebrospinal fluid revealed a neuroprotective effect of serelaxin treatment in both hypoxic and hypovolemic animals, whereas in control animals, neuroproteins increased during the experiment. Western blotting showed the expression of relaxin receptors and indicated region-specific differences in relaxin receptor-mediated signaling in cortical and subcortical brain arterioles, respectively. Our findings support the hypothesis that serelaxin is a potential neuroprotectant during hypoxia and hypovolemia. Due to its preferential improvement of cortical CBF, serelaxin might reduce cognitive impairments associated with these emergencies.
Competing Interests: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Besides that, the authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje